Renaissance Technologies’s Fibrocell Science Inc. FCSC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-763,754
Closed -$2.26M 3861
2019
Q3
$2.26M Buy
763,754
+23,300
+3% +$47.8K ﹤0.01% 2219
2019
Q2
$1.41M Buy
740,454
+204,015
+38% +$417K ﹤0.01% 2533
2019
Q1
$1.03M Buy
536,439
+99,798
+23% +$199K ﹤0.01% 2655
2018
Q4
$655K Buy
436,641
+68,700
+19% +$137K ﹤0.01% 2760
2018
Q3
$868K Buy
367,941
+205,660
+127% +$444K ﹤0.01% 2660
2018
Q2
$439K Buy
162,281
+138,742
+589% +$402K ﹤0.01% 2870
2018
Q1
$69K Sell
23,539
-2,220
-9% -$7.28K ﹤0.01% 3287
2017
Q4
$82K Buy
25,759
+2,006
+8% +$17.5K ﹤0.01% 3236
2017
Q3
$363K Buy
23,753
+2,100
+10% +$34K ﹤0.01% 2865
2017
Q2
$434K Buy
21,653
+4,280
+25% +$52.8K ﹤0.01% 2802
2017
Q1
$174K Buy
17,373
+4,440
+34% +$49.3K ﹤0.01% 3019
2016
Q4
$122K Buy
12,933
+9,460
+272% +$102K ﹤0.01% 3077
2016
Q3
$38K Buy
+3,473
New +$51.5K ﹤0.01% 3271
2016
Q2
Sell
-2,240
Closed -$84K 3607
2016
Q1
$84K Buy
+2,240
New +$89.4K ﹤0.01% 3234

Renaissance Technologies's FCSC Position: Q4 2019 in Review

Renaissance Technologies sold out of Fibrocell Science Inc. (FCSC) in Q4 2019, closing a stake of 763,754 shares — an estimated $2.26M sold.

Renaissance Technologies first reported a position in FCSC in Q1 2016 and held it in 14 quarters. The position peaked at $2.26M in Q3 2019. 0 funds tracked by Wall St. Rank hold FCSC as of Q4 2019.

  • Renaissance Technologies reported no remaining Fibrocell Science Inc. position as of Q4 2019 after selling out during the quarter.
  • Renaissance Technologies sold 763,754 Fibrocell Science Inc. shares in Q4 2019, an estimated $2.26M.
  • Renaissance Technologies first reported a position in Fibrocell Science Inc. in Q1 2016 and held it in 14 quarters.
  • Renaissance Technologies's Fibrocell Science Inc. position peaked at $2.26M in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Fibrocell Science Inc. as of Q4 2019.

Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.